Cellular immunotherapy compositions and uses thereof
AssigneeCero Therapeutics Holdings, Inc.
InventorDaniel Mark COREY
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to cellular immunotherapy compositions comprising a combination of immune cells or cellular subsets modified with chimeric engulfment receptors and chimeric antigen receptors/or T cell receptor binding proteins, and methods of using such cellular immunotherapy compositions.
Claims37
(canceled)
A combination cellular immunotherapy composition comprising:
- (a) a first composition comprising a CD4+ T cell comprising a chimeric engulfment receptor (CER) comprising:
- an extracellular domain comprising a Tim4 extracellular domain that binds to phosphatidylserine,
- an engulfment signaling domain, wherein the engulfment signaling domain comprises a TLR2 signaling domain;
- and
- a transmembrane domain positioned between and connecting the extracellular domain and the engulfment signaling domain;
- and
- (b) a second composition comprising a CD8+ T cell comprising:
- (i) a chimeric antigen receptor (CAR) comprising:
- an extracellular domain comprising an antibody binding domain that binds to a target antigen,
- an intracellular signaling domain, and
- a transmembrane domain positioned between and connecting the extracellular domain and the intracellular signaling domain;
- or
- (ii) a recombinant T cell receptor (TCR) that binds to a target antigen.
3-7. (canceled)
The combination cellular immunotherapy composition of 1 wherein:
- (a) the CAR binding domain comprises a scFv;
- and/or
- (b) the CAR extracellular domain further comprises a spacer domain between the antibody binding domain and the transmembrane domain.
(canceled)
-12. (canceled)
The combination cellular immunotherapy composition of claim 3, wherein the CAR intracellular signaling domain comprises a second costimulatory signaling domain selected from CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, and B7-H3 signaling domain.
(canceled)
(canceled)
(canceled)
-31. (canceled)
-34. (canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.